MAIA BIOTECHNOLOGY, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On February 13, 2023, MAIA Biotechnology, Inc. (the “Company”) issued a press
release announcing its intention to initiate its second Phase 2 clinical trial
evaluating THIO. Pursuant to Regulation FD, the press release is furnished with
this Current Report as Exhibit 99.1.

The information set forth in Item 7.01 of this Current Report on Form 8-K and in
the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to
be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section. The information set forth in Item 7.01 of this Current Report on Form
8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into
any filing under the Exchange Act or the Securities Act of 1933, as amended,
regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:



Exhibit No.   Description
99.1            Press release, dated as of February 13, 2023.
104           Cover Page Interactive Data File - the cover page XBRL tags are
              embedded within the Inline XBRL document.

——————————————————————————–

© Edgar Online, source Glimpses